c-Kit (Mast/stem cell growth factor receptor, SCFR or CD117) is a protein that in humans is encoded by the KIT gene. c-Kit (CD117) is an important cell surface marker used to identify certain types of hematopoietic (blood) progenitors in the bone marrow. c-Kit is a cytokine receptor expressed on the surface of hematopoietic stem cells as well as other cell types. Altered forms of this receptor may be associated with some types of cancer. c-Kit is a receptor tyrosine kinase type III, which binds to stem cell factor. When c-Kit binds to stem cell factor (SCF) it forms a dimer that activates its intrinsic tyrosine kinase activity, that in turn phosphorylates and activates signal transduction molecules that propagate the signal in the cell. Signalling through c-Kit plays a role in cell survival, proliferation, and differentiation.
## c-Kit Inhibitors & Modulators

### AC710
**Cat. No.: HY-13493**

**Bioactivity:** AC710 is a potent PDGFR inhibitor with $K_{d}$ of 0.6, 1.57, 1, 1.3, 10 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.

**Purity:** 98.03%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

### Amuvatinib hydrochloride
**Cat. No.: HY-10206A**

**Bioactivity:** Amuvatinib hydrochloride (MP470 hydrochloride) is a multi-targeted receptor tyrosine kinases inhibitor, which inhibits c-Kit (D816V), c-Kit (D816H), c-Kit (V560G), c-Kit (V654A), PDGFRα (D842V), and PDGFRα (V561D) with $IC_{50}$ of 950 nM, 10 nM, 34 nM, 127 nM, 81 nM, and 40 nM, respectively...

**Purity:** 99.36%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

### Amuvatinib
**Cat. No.: HY-10206**

**Bioactivity:** Amuvatinib (MP470) is a multi-targeted receptor tyrosine kinases inhibitor, which inhibits c-Kit (D816V), c-Kit (D816H), c-Kit (V560G), c-Kit (V564A), PDGFRα (D842V), and PDGFRα (V561D) with $IC_{50}$ of 950 nM, 10 nM, 34 nM, 127 nM, 81 nM, and 40 nM, respectively...

**Purity:** 99.36%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

### AST 487
**Cat. No.: HY-15002**

**Bioactivity:** AST 487 is a RET kinase inhibitor with $IC_{50}$ of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits Flt-3 with $IC_{50}$ of 520 nM.

**Purity:** 98.64%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

### Avapritinib
**Cat. No.: HY-101561**

**Bioactivity:** Avapritinib is a potent and selective exon 17 mutant KIT kinase inhibitor with $IC_{50}$ of 0.27 nM for KIT D816V.

**Purity:** 98.0%

**Clinical Data:** Phase 1

**Size:** 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

### AZD2932
**Cat. No.: HY-18179**

**Bioactivity:** AZD2932 is a potent and multi-targeted kinase inhibitor VEGFR2, PDGFRβ, Flt-3 and c-Kit with $IC_{50}$ of 8, 4, 7 and 9 nM in cell assay, respectively.

**Purity:** 98.12%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

### AZD3229
**Cat. No.: HY-112802**

**Bioactivity:** AZD3229 is a potent pan- KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors.

**Purity:** 99.55%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

### AZD3229 Tosylate
**Cat. No.: HY-112802A**

**Bioactivity:** AZD3229 Tosylate is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors.

**Purity:** 98.54%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

### c-Kit-IN-1
**Cat. No.: HY-15240**

**Bioactivity:** c-Kit-IN-1 is a potent inhibitor of c-Kit and c-Met with $IC_{50}$ of $<$200 nM.

**Purity:** 98.46%

**Clinical Data:** Phase 1

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

### c-Kit-IN-2
**Cat. No.: HY-128602**

**Bioactivity:** c-Kit-IN-2 is a c-Kit inhibitor with an $IC_{50}$ of 82 nM, shows superior antiproliferative activities against all the three GIST cell lines, GIST882, GIST430, and GIST48, with GI $SO_{50}$ of 3, 1, and 2 nM, respectively [1].

**Purity:** $>$98%

**Clinical Data:** No Development Reported

**Size:** 250 mg, 500 mg, 100 mg

---

Tel: 609-228-6898  Fax: 609-228-5909  Email: sales@MedChemExpress.com
Cabozantinib  
(XL184; BMS-907351)  
Cat. No.: HY-13016

Bioactivity: Cabozantinib is a potent multiple receptor tyrosine kinase inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50 of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

Purity: 99.92%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

CHMFL-KIT-033
Cat. No.: HY-128589

Bioactivity: CHMFL-KIT-033 is a potent and selective inhibitor of c-KIT T670I mutant for gastrointestinal stromal tumors (GISTs), with an IC50 of 0.045 μM [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg, 500 mg

Dovitinib  
(CHIR-258; TKI258)  
Cat. No.: HY-50905

Bioactivity: Dovitinib is a multi-targeted tyrosine kinase inhibitor with IC50 of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively.

Purity: 99.31%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Flumatinib  
(HHG678)  
Cat. No.: HY-13904

Bioactivity: Flumatinib (HHG678) is a multi-kinase inhibitor with IC50 Values of 1.2 nM, 307.6 nM and 2662 nM for c-Abl, PDGFRβ and c-Kit respectively.

Purity: 99.94%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

Flumatinib mesylate  
(HHG678 mesylate)  
Cat. No.: HY-13905

Bioactivity: Flumatinib mesylate (HH-GV-678 mesylate), a derivative of imatinib, is a multi-kinase inhibitor with IC50 Values of 1.2 nM, 307.6 nM and 2662 nM for c-Abl, PDGFRβ and c-Kit respectively. IC50 Value: 1.2 nM (c-Abl); 307.6 nM(PDGFRβ); 2662 nM (c-Kit) [1] Target: c-Abl; c-Kit; PDGFRβ in vitro:…

Purity: 95.0%
Clinical Data: Phase 3
Size: 10mM x 1mL in Water, 500 mg

Imatinib  
(STI571; CGP-57148B)  
Cat. No.: HY-15463

Bioactivity: Imatinib (STI571) is a tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.

Purity: 99.80%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 200 mg, 500 mg, 1 g, 5 g

Imatinib Mesylate  
(STI571 (Mesylate); CGP-57148B (Mesylate))  
Cat. No.: HY-50946

Bioactivity: Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.

Purity: 99.91%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg, 1 g, 5 g

ISCK03  
Cat. No.: HY-101443

Bioactivity: ISCK03 is a specific SCF/c-Kit inhibitor.

Purity: 98.82%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Masitinib  
(AB1010)  
Cat. No.: HY-10209

Bioactivity: Masitinib is an orally available Kit inhibitor with an IC50 of 200 nM. It also inhibits PDGFRα/β with an IC50 of 540 nM/800 nM.

Purity: 99.94%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg

Masitinib mesylate  
(AB-1010 mesylate)  
Cat. No.: HY-10209A

Bioactivity: Masitinib mesylate is a novel inhibitor for Kit and PDGFRα/β with IC50 of 200 nM and 540 nM/800 nM, and has weak inhibition to ABL and c-Fms.

Purity: 99.31%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg

www.MedChemExpress.com
**Motesanib**
*(AMG 706; )
Cat. No.: HY-10228

Bioactivity: Motesanib is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC\textsubscript{50} of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is 10-fold more selective for VEGFR than PDGFR and Ret.

Purity: 99.75%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 50 mg, 100 mg

**Motesanib Diphosphate**
*(AMG 706 (Diphosphate))
Cat. No.: HY-10229

Bioactivity: Motesanib Diphosphate is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC\textsubscript{50} of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is approximately 10-fold more selective for VEGFR than PDGFR and Ret.

Purity: 99.64%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg

**OSI-930**
Cat. No.: HY-10204

Bioactivity: OSI-930 is a potent inhibitor of Kit, KDR and CSF-1R with IC\textsubscript{50} of 80 nM, 9 nM and 15 nM, respectively, also potent to Flt-1, c-Raf and Lck and low activity against PDGFRα/β. Flt-3 and Abl. IC\textsubscript{50} value: 9 nM (VEGFR2); 15 nM (CSF1R); 80 nM (Kit activated) [1] Target: VEGFR2/Kit/CSF1R in vitro: OSI-930...

Purity: 97.23%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

**Pazopanib**
*(GW786034)
Cat. No.: HY-10208

Bioactivity: Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC\textsubscript{50} of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

Purity: 99.68%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

**Pazopanib Hydrochloride**
*(GW786034 (Hydrochloride))
Cat. No.: HY-12009

Bioactivity: Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC\textsubscript{50} of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

Purity: 99.92%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

**Pexidartinib**
*(PLX-3397; PLX-3397 hydrochloride)
Cat. No.: HY-16749A

Bioactivity: Pexidartinib hydrochloride (PLX-3397 hydrochloride) is a potent, selective and ATP-competitive and CSF1R (cFMS) inhibitor, with IC\textsubscript{50} of 20 and 10 nM, respectively. Pexidartinib exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Anti-cancer activity... 

Purity: 99.50%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

**PLX647**
Cat. No.: HY-13838

Bioactivity: PLX647 is a highly specific dual FMS/KIT kinase inhibitor with IC\textsubscript{50} of 28/16 nM respectively. IC\textsubscript{50} value: 28/16 nM/FMS/KIT [1] Target: FMS/KIT dual inhibitor in vitro: PLX647 was tested against a panel of 400 kinases at a concentration of 1 μM, 35-fold above its FMS enzymatic IC\textsubscript{50} and 60-fold above its KIT... 

Purity: 98.20%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

**Ripretinib**
*(DCC-2618)
Cat. No.: HY-112306

Bioactivity: Ripretinib (DCC-2618) is a pan- KIT and PDGFRα inhibitor, and has antitumor activity.

Purity: 99.46%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

**Sitravatinib**
*(MGCD516; MG516)
Cat. No.: HY-16961

Bioactivity: Sitravatinib (MGCD516; MG516) is an orally bioavailable, receptor tyrosine kinase (RTK) inhibitor with IC\textsubscript{50} of 1.5 nM, 2 nM, 2 nM, 5 nM, 5nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DD... 

Purity: 99.85%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg
### SU14813

<table>
<thead>
<tr>
<th>Bioactivity:</th>
<th>SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with IC₅₀ of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purity:</td>
<td>99.49%</td>
</tr>
<tr>
<td>Clinical Data:</td>
<td>No Development Reported</td>
</tr>
<tr>
<td>Size:</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</td>
</tr>
</tbody>
</table>

**SU14813 maleate**

<table>
<thead>
<tr>
<th>Bioactivity:</th>
<th>SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC₅₀ of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purity:</td>
<td>99.34%</td>
</tr>
<tr>
<td>Clinical Data:</td>
<td>No Development Reported</td>
</tr>
<tr>
<td>Size:</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</td>
</tr>
</tbody>
</table>

### Telatinib (Bay 57-9352)

<table>
<thead>
<tr>
<th>Bioactivity:</th>
<th>Telatinib (Bay 57-9352) is an orally active, small molecule inhibitor of VEGFR2, VEGFR3, PDGFα, and c-Kit with IC₅₀ of 6, 4, 15 and 1 nM, respectively.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purity:</td>
<td>99.49%</td>
</tr>
<tr>
<td>Clinical Data:</td>
<td>Phase 2</td>
</tr>
<tr>
<td>Size:</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>